Actinogen Medical Ltd
3AC
Company Profile
Business description
Actinogen Medical Ltd is a biotechnology company. The company develops drugs for Alzheimer's disease and the cognitive decline associated with other neurological diseases. It is focused on the clinical development of Xanamem, an oral medication for neurological diseases amenable to its mechanism of lowering cortisol in brain cells. Geographically, the company's income is derived in Australia.
Contact
109 Pitt Street
Level 9, Suite 901
SydneyNSW2000
AUST: +61 289647401
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
Stocks News & Analysis
stocks
Another incredible quarter from Microsoft
We were wrong when we thought last quarter would be hard to top.
stocks
10 best US dividend aristocrats to buy now—including a surprise outperformer
These undervalued stocks with wide and narrow moats have increased their dividends for 25 consecutive years or more.
stocks
Leading ASX players in this field look materially overvalued
We raise our Fair Value estimates but still think that current share prices rely on overly optimistic expectations.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,999.00 | 16.40 | -0.18% |
CAC 40 | 7,878.10 | 16.14 | 0.21% |
DAX 40 | 24,395.74 | 133.52 | 0.55% |
Dow JONES (US) | 44,461.28 | 171.71 | -0.38% |
FTSE 100 | 9,166.43 | 29.49 | 0.32% |
HKSE | 24,773.33 | 403.60 | -1.60% |
NASDAQ | 21,129.67 | 31.38 | 0.15% |
Nikkei 225 | 41,069.82 | 415.12 | 1.02% |
NZX 50 Index | 12,823.74 | 32.23 | -0.25% |
S&P 500 | 6,362.90 | 7.96 | -0.12% |
S&P/ASX 200 | 8,742.80 | 13.60 | -0.16% |
SSE Composite Index | 3,573.21 | 42.51 | -1.18% |